Cue Biopharma (CUE) AI Stock Analysis

• Market Cap: $21.99M
• Dividend Yield: N/A
• Average Volume (3M): 238.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: -25.51%
• EPS Growth: 49.72%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 91,237,740
• 10 Day Avg. Volume: 365,762
• 30 Day Avg. Volume: 238,588
• PEG Ratio: 0.04
• Price to Book (P/B): 3.51
• Price to Sales (P/S): 6.61
• P/FCF Ratio: -1.69
• Enterprise Value/Market Cap: 2.06
• Enterprise Value/Revenue: 6.38
• Enterprise Value/Gross Profit: 6.45
• Enterprise Value/Ebitda: -1.28
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.26 ▼(-24.41% Downside)

The overall stock score is primarily impacted by significant financial challenges and bearish technical indicators. While recent corporate events provide some positive outlook, the financial and technical weaknesses weigh heavily on the score.

Positive Factors

Strategic Partnership

The partnership with ImmunoScape enhances Cue Biopharma's focus on autoimmune disease programs and advances its Immuno-STAT platform, potentially leading to breakthroughs in T cell therapy with improved efficacy and tolerability.

Cash Runway Extension

The $10 million equity offering extends the company's cash runway, potentially alleviating near-term financing pressure and supporting continued operations and development activities.

New Leadership

The appointment of Usman Azam as CEO brings experienced leadership to Cue Biopharma, which may enhance strategic direction and operational capabilities, potentially improving market positioning and stakeholder confidence.

Negative Factors

Revenue Decline

Declining revenue growth indicates challenges in market penetration and product adoption, which could hinder long-term financial performance and strategic initiatives.

Negative Profit Margins

Deeply negative profit margins reflect significant operational inefficiencies and financial challenges, which may impact the company's ability to invest in growth and innovation.

Cash Flow Challenges

Negative cash flow ratios indicate difficulties in generating sufficient cash to cover expenses, potentially limiting the company's ability to sustain operations and invest in future growth.

Cue Biopharma Business Overview & Revenue Model

Company Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at harnessing the body's immune system to fight cancer and autoimmune diseases. The company operates primarily in the biopharmaceutical sector, specializing in its proprietary Cue Biologics platform, which enables the design of biologics to selectively modulate immune responses. Cue Biopharma's core products include immune modulators that target specific T cell populations, with several candidates currently in clinical trials for various indications.

How the Company Makes Money

Cue Biopharma generates revenue through a combination of clinical trial partnerships, research collaborations, and potential milestone payments from its pharmaceutical partners. The company often enters into partnerships with larger pharmaceutical firms, which provide funding for the development of its drug candidates in exchange for rights to commercialize the products. Additionally, Cue Biopharma may receive royalties on future sales of successful therapies. The company's revenue model is heavily reliant on the success of its clinical trials, as positive results can lead to increased interest from potential partners and investors.

Cue Biopharma Financial Statement Overview

Summary

Cue Biopharma is facing significant financial challenges, characterized by persistent losses and negative cash flows. While there is some revenue growth, the company's profitability and cash generation remain under pressure. The balance sheet shows moderate leverage, but the negative return on equity and ongoing cash burn pose risks to financial stability.

Income Statement

Cue Biopharma's income statement reveals significant challenges in profitability, with negative net profit margins and EBIT margins over the TTM period. Although there is a slight revenue growth, the company struggles with high operating losses, indicating inefficiencies in cost management. The gross profit margin is relatively high, suggesting potential for improvement if operational costs are controlled.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. However, the negative return on equity highlights the company's inability to generate profits from shareholders' investments. The equity ratio is stable, but the overall financial health is weakened by consistent losses.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow, reflecting ongoing cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that cash outflows are closely aligned with net losses. The company faces challenges in generating positive cash flows, which could impact its liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.10M	9.29M	5.49M	1.25M	14.94M	3.15M
Gross Profit	7.02M	9.29M	-32.61M	1.25M	16.72M	-30.39M
EBITDA	-35.43M	-37.53M	-46.05M	-50.49M	-45.44M	-43.99M
Net Income	-37.68M	-40.67M	-50.73M	-53.01M	-44.16M	-44.78M
Balance Sheet
Total Assets	31.64M	32.19M	61.53M	91.28M	83.40M	99.53M
Cash, Cash Equivalents and Short-Term Investments	18.67M	23.39M	48.51M	76.29M	64.37M	84.87M
Total Debt	6.17M	8.88M	14.70M	19.32M	12.02M	7.15M
Total Liabilities	18.40M	14.69M	24.45M	25.60M	17.91M	20.62M
Stockholders Equity	13.25M	17.50M	37.09M	65.68M	65.49M	78.91M
Cash Flow
Free Cash Flow	-29.82M	-36.40M	-39.96M	-41.98M	-39.75M	-33.09M
Operating Cash Flow	-29.64M	-36.33M	-39.96M	-41.81M	-38.84M	-32.49M
Investing Cash Flow	-6.95M	32.00K	25.00M	-24.61M	9.11M	4.46M
Financing Cash Flow	15.87M	10.24M	11.86M	53.66M	19.23M	58.61M

Cue Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.61, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 13.05 is Positive, neither overbought nor oversold. The STOCH value of 4.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUE.

Cue Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAIA	44 Neutral	$54.81M	-1.99	-2691.06%	―	―	44.50%
CUE	42 Neutral	$21.99M	-0.53	-195.19%	―	-25.51%	49.72%
ALGS	40 Underperform	$64.74M	-0.53	-141.82%	―	-55.88%	6.14%
CELU	38 Underperform	$37.59M	-0.40	―	―	-15.81%	-113.06%
ACRV	36 Underperform	$75.42M	-1.12	-50.23%	―	―	21.17%

Cue Biopharma Corporate Events

Cue Biopharma Announces $10 Million Public Equity Offering

On December 19, 2025, Cue Biopharma priced an underwritten public offering of 35,714,286 shares of common stock, or pre-funded warrants in lieu of shares, together with accompanying common stock warrants to purchase 17,857,143 shares, at a combined price of $0.28 per share-and-warrant unit (or $0.279 for units with pre-funded warrants), for expected gross proceeds of about $10 million before fees and expenses. All securities in the deal are being sold by the company, with H.C. Wainwright & Co. acting as sole bookrunner and Newbridge Securities as co-manager, and the underwriters have been granted a 30-day option to purchase up to an additional 5,357,140 shares and/or 2,678,570 warrants; the offering, expected to close around December 22, 2025, is projected, together with existing cash, marketable securities and payments from its ImmunoScape collaboration, to fund Cue Biopharma’s operations into the first quarter of 2027, extending its cash runway and potentially alleviating near-term financing pressure for stakeholders despite the dilutive impact of the equity and warrant issuance.

Cue Biopharma Releases Updated Corporate Presentation

On November 24, 2025, Cue Biopharma, Inc. made an updated corporate presentation available on its website. This announcement does not affect the company’s filings under the Securities Exchange Act of 1934 or the Securities Act of 1933, unless specifically referenced.

Cue Biopharma Announces CMO Departure

On November 17, 2025, Cue Biopharma, Inc. announced the termination of employment for its Chief Medical Officer, Dr. Matteo Levisetti, effective November 28, 2025. Dr. Levisetti will receive severance benefits, including a lump sum cash payment and continued health insurance coverage under COBRA, as part of his separation agreement.

Cue Biopharma Partners with ImmunoScape for Cell Therapy

On November 6, 2025, Cue Biopharma and ImmunoScape announced a strategic collaboration to develop a novel cell therapy approach for solid tumors. This agreement allows ImmunoScape to research, develop, and commercialize molecules from Cue Biopharma’s CUE-100 Series, aiming to advance a ‘Seed-and-Boost’ immunotherapy approach. The collaboration is expected to enhance Cue Biopharma’s focus on autoimmune disease programs and advance its Immuno-STAT platform in oncology, potentially providing a breakthrough in T cell therapy with improved efficacy and tolerability. Cue Biopharma will receive significant financial benefits, including equity in ImmunoScape and royalties from future sales.

Cue Biopharma Appoints Usman Azam as New CEO

On September 26, 2025, Cue Biopharma announced the appointment of Usman Azam as the new President and CEO, effective September 29, 2025, succeeding Daniel R. Passeri who will retire but remain as a strategic advisor. Dr. Azam’s extensive experience in leading biopharmaceutical companies is expected to enhance Cue Biopharma’s strategic direction and operational capabilities, potentially impacting its market positioning and stakeholder interests.